Sinovac Biotech Ltd.
SVA · NASDAQ
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | 119.3% | -49.9% | – |
| Cost of Goods Sold | – | $0 | $0 | $0 |
| Gross Profit | – | $0 | -$0 | -$0 |
| % Margin | – | 100% | -34.2% | -53.3% |
| R&D Expenses | – | $0 | $0 | $0 |
| G&A Expenses | – | $0 | $0 | $0 |
| SG&A Expenses | – | $0 | $0 | $1 |
| Sales & Mktg Exp. | – | $0 | $0 | $0 |
| Other Operating Expenses | – | $0 | $0 | $0 |
| Operating Expenses | – | $0 | $0 | $1 |
| Operating Income | – | -$0 | -$0 | -$1 |
| % Margin | – | -40% | -306.7% | -384.5% |
| Other Income/Exp. Net | – | $0 | $0 | $1 |
| Pre-Tax Income | – | -$0 | -$0 | -$1 |
| Tax Expense | – | $0 | -$0 | -$0 |
| Net Income | – | -$0 | $0 | -$0 |
| % Margin | – | -38% | 12% | -132.2% |
| EPS | – | -1.17 | 0.17 | -3.73 |
| % Growth | – | -788.2% | 104.6% | – |
| EPS Diluted | – | -1.17 | 0.15 | -3.73 |
| Weighted Avg Shares Out | – | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | – | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $0 | $0 | $0 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | – | $0 | $0 | -$0 |
| EBITDA | – | -$0 | $0 | -$1 |
| % Margin | – | -8.7% | 14.8% | -356.4% |